CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Saline containing 1% Human serum albumin（solution of MSC）Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug928 bacTRL-Spike Wiki 1.00
drug486 MSCs Wiki 0.71
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.11
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Human Mesenchymal Stem Cells in Combination With Standard Therapy in the Treatment of COVID-19 Patients With Severe Convalescence

COVID-19 caused clusters of severe respiratory illness and was associated with 2% mortality. No specific anti-viral treatment exists. The mainstay of clinical management is largely symptomatic treatment, with organ support in intensive care for seriously ill patients. Cellular therapy, using mesenchymal stem cells has been shown to reduce nonproductive inflammation and affect tissue regeneration and is being evaluated in patients with ARDS. This clinical trial is to inspect the safety and efficiency of mesenchymal stem cells (MSCs) therapy for severe COVID-19.

NCT04288102 Corona Virus Disease 2019(COVID-19) Biological: MSCs Biological: Saline containing 1% Human serum albumin（solution of MSC）
MeSH:Coronavirus Infections Virus Diseases

Primary Outcomes

Description: Evaluation of Pneumonia Improvement

Measure: Size of lesion area and severity of pulmonary fibrosis by chest CT

Time: At Baseline , Day 6, Day 10, Day 14, Day 28 and Day 90

Secondary Outcomes

Description: Evaluation of Pneumonia Improvement No limitation of activities, discharged from hospital =Score 1; Hospitalized, no oxygen therapy=Score 2; Oxygen by mask or nasal prongs-Score 3; Non-invasive ventilation or high-flow oxygen=Score 4; Mechanical ventilation or ECMO=Score 5; Death=Score 6.

Measure: mMRC (Modified Medical Research Council) dyspnea scale

Time: Baseline , Day 7, Day 14, Day 28, Day 90

Description: Evaluation of Pneumonia Improvement

Measure: Oxygenation index( PaO2/FiO2)

Time: Baseline , Day 7, Day 14, Day 28, Day 90

Description: Evaluation of Pneumonia Improvement

Measure: Duration of oxygen therapy(days)

Time: Day 28, Day 90

Description: Evaluation of Pneumonia Improvement

Measure: Duration of hospitalization(days)

Time: Day 28, Day 90

Description: Evaluation of Pneumonia Improvement

Measure: Blood oxygen saturation

Time: Baseline , Day 7, Day 14, Day 28, Day 90

Description: Marker of Immunological function

Measure: CD4+ T cell count and cytokine level

Time: Baseline , Day 6, Day 10, Day 14, Day 21, Day 28, Day 90

Description: Proportion of participants with treatment-related adverse events as assessed by CTCAE v4.0

Measure: Side effects in the MSCs treatment group

Time: Baseline , Day 3, Day 6，Day 10, Day 14, Day 21, Day 28, Day 90

Description: Evaluation of Pneumonia Improvement

Measure: 6-minute walk test

Time: Baseline, Day 10, Day 14, Day 21, Day 28, Day 90

Description: Evaluation of Pneumonia Improvement

Measure: Maximum vital capacity (VCmax)

Time: Baseline, Day 10, Day 14, Day 21, Day 28, Day 90

Description: Evaluation of Pneumonia Improvement

Measure: Diffusing Capacity (DLCO)

Time: Baseline, Day 10, Day 14, Day 21, Day 28, Day 90

No related HPO nodes (Using clinical trials)